dhr. dr. M.D. Njoo

Aandachtsgebieden

CV

BIG-nummer

Wetenschappelijke publicaties en onderzoeken

• Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study

  Haar ELM ter, Thomas SE, Reek JMPA van den , Otero ME, Njoo MD, Ossenkoppele PM, Et al. .
  Drugs Aging 2022; : Doi: 10.1007/s40266-022-00961-y. Online ahead of print..
  

• Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry

  Schoot LS van der, Groenewoud HJM, Gelder MMH van , Otero ME, Arnold WP, Berends MAM, Bruin-Weller MS de, Dodemont SRP, Ossenkoppele PM, Njoo MD, Et al. .
  JEADV Clin Pract. 2022; 2(1):1-14.
  

• Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort

  Muijen ME van, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD, Dodemont SRP, Kop EN, Berends MAM, et al. .
  Acta Derm Venereol. 2022; :Doi: 10.2340/actadv.v102.206..
  

• Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

  Atalay S, Berends SE, Groenewoud HMM, Mathot RAA, Njoo MD, Mommers JM, Ossenkoppele PM, Koetsier MIA.
  J Dermatolog Treat. 2022; :doi: 10.1080/09546634.2022.2043546. Online ahead of print.
  

• Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study

  Atalay S, Reek JMPA van den, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, Koetsier MI, Berends MM, Kerkhof PCM van de, Groenewoud HMM, Broeder AA den , Jong EMGJ de, Kievit W.
  Acta Derm Venereol. 2020; :doi: 10.2340/00015555-3692. Online ahead of print..
  

• Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial

  Atalay S, Reek JMP van den, Broeder AA den, Vugt LJ van, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM.
  JAMA Dermatol. 2020; 156(4):393-400.
  

• Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.

  Schoot LS van der, Reek JM van den, Groenewoud JM, Otero ME, Njoo MD, Ossenkoppele PM, Mommers JM, Koetsier MI, Berends MA, Arnold WP.
  J Eur Acad Dermatol Venereol 2019; :doi: 10.1111/jdv.15733. [Epub ahead of print].
  Publicatie openen

• Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

  Reek JM van den, Vugt LJ van, Doorn MB van, Kraaij GE van der, Kort WJ de , Lucker GP, Horvath B, Njoo MD, Ossenkoppele PM.
  Acta Derm Venereol. 2018; :doi: 10.2340/00015555-2900. [Epub ahead of print].
  

• Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice

  Zweegers J, Groenewoud JM, Reek JM van den , Otero ME, Kerkhof PC van de, Driessen RJ, Njoo MD, Ossenkoppele PM.
  Br J Dermatol 2017; 176(4):1001-1009.
  Publicatie openen

• Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice

  Zweegers J, Roosenboom B, Kerkhof PC van de , Reek JM van de , Otero ME, Atalay S, Kuijpers AL, Koetsier MI, Arnold WP, Bijen M, Njoo MD.
  Br J Dermatol 2017; 176(3):786-793.
  Publicatie openen

• Twenty-year follow-up using a postal survey of childhood vitiligo treated with narrowband ultraviolet B phototherapy

  Lommerts JE, Njoo MD, Rie MA de , Wolkenstorfer A, Bekkenk MW.
  Br J Dermatol 2017; :10.1111/bjd.15337.
  Publicatie openen

• Body mass index predicts discontinuation due to ineffctiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice...

  Zweegers J, Reek JM van den , Kerkhof PC van den , Otero ME, Kuijpers AL, Koetsier MI, Arnold WP, Berends MA, Weppner-Parren L, Ossenkoppele PM, Njoo MD.
  Br. J. Dermatol. 2016; 175(2):340-7.
  

• 'Happy' Drug Survival of Adalimumab, Etanercept and Ustekinumab in Psoriasis in Daily Practice Care - Results from the BioCAPTURE network

  Reek JM van den, Zweegers J, Kievit W, Otero ME, Lümig PP van, Driessen RJ, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, Kerkhof PC van de, Seyger MM, Jong EM de.
  Br J Dermatol 2014; :doi: 10.1111/bjd.13087 [Epub ahead of print].
  Publicatie openen

• Satisfaction with medication is high for biologics in psoriasis. Results from the BioCAPTURE network

  Reek JM van den, Lümig PP, Otero ME, Zweegers J, Kerkhof PC van de, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, Seyger MM, Kievit W, Jong de.
  Br J Dermatol 2014; :doi:. 10.1111/bjd.12862 [Epub ahead of print].
  Publicatie openen